News
Article
AMRI Announces Increased Production of Hydroxychloroquine Sulfate for COVID-19 Treatment
Author(s):
FDA approved hydroxychloroquine sulfate for emergency use as a treatment for some hospitalized patients with COVID-19.
AMRI, a contract research development and manufacturing organization, announced on April 30, 2020 that it will be increasing its production of hydroxychloroquine sulfate (HCQ) API at its Rensselaer, NY, manufacturing facility to assist in the fight against COVID-19.
According to a company press release, FDA approved HCQ for emergency use as a treatment for some hospitalized patients with COVID-19.
“We look forward to working with our drug product producers, government agencies, and associated health authorities globally to ensure access to this API, as needed,” said the company in the press release.
Source: AMRI
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
